26th JSSX Annual Meeting in Hiroshima!
November 17, 2011!

EXPECTATIONS FOR THE NEXTGENERATION JSSX	
President of JSSX !
President of Kyoto Pharmaceutical University!

Ken-ichi Inui!

Constitution of JSSX Members (Oct., 2011)	  Academia	
Companies	
Hospitals	
Others	Students	
Total	

527	
1001	
114	
95	
362	
2119	

Missions as the President of JSSX		  	  	  	  For	  Strong	  Structure	  of	  JSSX	  (Academia,	  Pharmaceu8cal	  Companies,	  Hospitals	  and	  etc.),	  and	  	  	  	  	  	  Dis8nc8ve	  and	  ABrac8ve	  Academic	  Society	  in	  the	  Field	  of	  Medicine	  and	  Pharmaceu8cal	  Sciences:	  1. Activation and Enrichment in the JSSX Annual Meeting!
2. DMPK, More Attractive Journal for Authors and Readers!
3. Globalization of JSSX and the Partnership with ISSX!

Directors (2011) !
President	  	  President-­‐Elect	  	  Ken-­‐ichi	  Inui,	  Prof.,	  Ph.D.	  

Hiroshi	  Suzuki,	  Prof.,	  Ph.D.	  

Takashi	  Igarashi,	  Ph.D.	  

Takashi	  Izumi,	  Ph.D.	  	  Teruko	  Imai,	  Prof.,	  Ph.D.	  

Shigeru	  Ohta,	  Prof.,	  Ph.D.	  

Toshiyuki	  Kume,	  Ph.D.	  	  Hideyuki	  Saito,	  Prof.,Ph.D.	  

Mikihisa	  Takano,	  Prof.,	  Ph.D.	  

Ikumi	  Tamai,	  Prof.,	  Ph.D.	  

Kan	  Chiba,	  Prof.,	  Ph.D.	  

Takahiko	  Baba,	  Ph.D.	  	  Kyoto	  Pharmaceu8cal	  	  University	  	  	   The	  University	  of	  Tokyo	  Hospital	  	  Nippon	  Boehringer	  Ingelheim	  Co.,	  Ltd.	  	  Mitsubishi	  Tanabe	  Pharma	  	  Corpora8on	  Inc.	  	  Kumamoto	  University	  Hospital	  Masakiyo	  Hosokawa,	  Prof.,	  Ph.D.	  
Chiba	  Ins8tute	  of	  Science	  Hiroshima	  University	  Toshiya	  Moriwaki,	  	  Ph.D.	  

Takeda	  Pharmaceu8cal	  Company	  	  Daiichi	  Sankyo	  Co.,	  Ltd.	  

Kanazawa	  University	  Hiroshi	  Yamazaki,	  Prof.,	  Ph.D.	  
Showa	  Pharmaceu8cal	  University	  Kumamoto	  University	  Chiba	  University	  Yamada	  Hideyuki,	  Prof.,	  Ph.D.	  
Kyushu	  University	  Hiroshima	  University	  Shionogi＆	  Co.,	  Ltd.	  

Tsuyoshi	  Yokoi,	  Prof.,	  Ph.D.	  
Kanazawa	  University	  Directors (2010) !
President	  	  Kenichi	  Inui,	  Prof.,	  Ph.D.	  

President-­‐Elect	  	  Hiroshi	  Suzuki,	  Prof.,	  Ph.D.	  

Takashi	  Igarashi,	  Ph.D.	  

Takashi	  Izumi,	  Ph.D.	  	  Teruko	  Imai,	  Prof.,	  Ph.D.	  

Shigeru	  Ohta,	  Prof.,	  Ph.D.	  

Hideyuki	  Saito,	  Prof.,Ph.D.	   Mikihisa	  Takano,	  Prof.,	  Ph.D.	  

Ikumi	  Tamai,	  Prof.,	  Ph.D.	  

Toshio	  Teramura,	  Ph.D.	  	  Takahiko	  Baba,	  Ph.D.	  	  Masahiro	  Hayashi,	  Prof.,	  Ph.D.	  

Kyoto	  Pharmaceu8cal	  	  University	  	  	   The	  University	  of	  Tokyo	  Hospital	  	  Nippon	  Boehringer	  Ingelheim	  Co.,	  Ltd.	  	  Kumamoto	  University	  Hospital	  Hiroshima	  University	  Masakiyo	  Hosokawa,	  Prof.,	  Ph.D.	  
Chiba	  Ins8tute	  of	  Science	  Kanazawa	  University	  Toshiya	  Moriwaki,	  	  Ph.D.	  

Takeda	  Pharmaceu8cal	  Company	  	  Daiichi	  Sankyo	  Co.,	  Ltd.	  

Astellas	  Pharama	  Inc.	  	  Hiroshi	  Yamazaki,	  Prof.,	  Ph.D.	  
Showa	  Pharmaceu8cal	  University	  Kumamoto	  University	  Shionogi＆	  Co.,	  Ltd.	  

Yamada	  Hideyuki,	  Prof.,	  Ph.D.	  
Kyushu	  University	  Hiroshima	  University	  Tokyo	  University	  of	  Pharmacy	  	  and	  Life	  Sciences	  Tsuyoshi	  Yokoi,	  Prof.,	  Ph.D.	  
Kanazawa	  University	  Auditors	  Toshio	  Suwa,	  Prof.,	  Ph.D.	   Yoshinobu	  Yoshimura,	  Ph.D.	  
Keio	  University	  	   Takeda	  Analy8cal	  Research	  Laboratories	  	  Secretariat	  	  Editorial	  oﬃce	  	  Editor	  in	  Chief,	  	  DMPK	  

execu8ve	  director	  Sudo	  Kenichi,	  Ph.D.	  
Yoshimi	  Chiba	  DAIICHI	  SANKYO	  RD	  ASSOCIE	  CO.,LTD	  	  Hiromi	  Nishizawa	  Editor	  in	  Chief,	  	  DMPKNewsLeBer	  Ikumi	  Tamai,	  Prof.,	  Ph.D.	   Hiroaki	  Yuasa,	  Prof.,	  Ph.D.	  
Kanazawa	  University	  Nagoya	  City	  University	  Maki	  Sakai	  Committees !
◆General Affairs Committee	

（Mikihisa Takano ）	

◆Finance Committee	

（Takahiko Baba）	

◆DMPK Editorial Committee	（Ikumi Tamai）	

◆DMPK Support Committee	

（Teruko Imai）	

◆International Affairs Committee 	（Hiroshi Yamazaki）	

◆The Society Activation and Planning Committee	 （Hideyuki Saito）	
◆Future Perspective Committee	

（Hiroshi Suzuki）	

◆Forum Committee	

（Hideyuki Yamada）	

◆Newsletter Editorial Committee	

（Hiroaki Yuasa）	

History of JSSX and toward theGlobalization	
December	  14,	  1985 	  Established	
1986	  	  	  Publica8on	  of	  “Yakubutudoutai”	
1986	  	  	  1st	  JSSX	  annual	  mee8ng	  in	  Toyama（Chair：Tamotsu	  Koizumi）	
1989 1st	  JSSX	  Workshop	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  （Manager：Hideyo	  Shindo,Toshio	  	  Nanbara,	  Hiroshi	  Miyazaki）	
2002 Publica8on	  of	  “Drug	  Metabolism	  and	  Pharmacokine8cs(DMPK)”	
2004 Abstract	  of	  DMPK	  has	  been	  appeared	  in	  PubMed	  2004 19th	  JSSX	  Annual	  Mee8ng	  in	  Kanazawa	  (Abstract	  in	  English)	  2005 Joint	  13th	  North	  American	  ISSX	  /	  20th	  JSSX	  Mee8ng	  in	  Hawaii	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  （Chair：Tetsuya	  Kamataki）	
2009 Impact	  factor	  of	  DMPK	  （2.641）	  2009 24th	  JSSX	  Annual	  Mee8ng	  in	  Kyoto	  (English	  as	  oﬃcial	  language)	  2010 25th	  	  JSSX	  Annual	  Mee8ng	  in	  Tokyo	  (Anniversary	  Symposium)	  Globalization of Meeting	
25th	  	  JSSX	  Annual	  Mee8ng	  in	  Tokyo	  (Oct.,	  2009)	
Submitted Abstracts (289)	

Total Attendees (1,116)	

Oral!
(108)	

Poster!
(181)	

Japanese! Foreigner!
(1,092)	
(24)	

Japan!

103!

177!

Member!

591!

5!

Taiwan	2!

1!

Non-member	

262!

5!

Thailand	

0!

2!

Graduatestudent 	

146!

7!

New Zealand	

1!

1!

Under
graduate	30!

0!

Indonesia	

1!

0!

Invited	

63!

7!

Germany	1!

0!

Domes'c	  (734)	

Abroad	  (19)	

Member	444	

4	

Non-­‐member	

135	

4	

Graduate	  Student	

101	

6	

Under	  Graduate	26	0	

Invited	28	

5	

Workshops and Short Courses of JSSX	Year	Themes	25th Workshop of JSSX
“Stop the termination of new drug development due to toxicity-What can be done by pharmacokinetics researchers?-”	

2011	 5th Short CourseAttendees	

250“The Front Lines for Corporate Research on Induction and Metabolism usingCells.”	

168	

24th Workshop of JSSX“The advantage of PPK-PD approaches for drug development.”	

271	

2010	 4th Short Course“How to conduct ADME research for effectively producing new drugs at thedrug discovery stage using biomarkers and the PK/PD approach. - Striving for
improving the success rate of clinical POC acquisition. –”	
23rd Workshop of JSSX“A New Phase of ADME-TOX (Absorption, Distribution, Metabolism,Excretion and Toxicity) for Safe Drug Discovery.”	

2009	 3rd Short Course“Application of Transporter (Transmembrane) Study in New Drug
Development.”	

137	298	
144	

Drug Metabolism and Pharmacokinetics(DMPK), Official Journal of JSSX	
1. New Editorial Committee from 2010 (Including Two Foreign Boards).!
2. Grants-in-Aid for Scientific Research was Received from 2008 to 2011.
(3,400,000 – 4,400,000 yen)!
3. Theme Issue was Published. !
4. Impact Factor of 2010 was 2.558.!
5. Increase of Submitted Manuscript. !
6. Rejection Ratio is around 40%.!

Impact Factors of Japanese Journals	
3	  Drug	  Metab	  Pharmacokinet	  2	  J	  Pharmacol	  Sci	  J	  Biochem	  1	  Biol	  Pharm	  Bull	  Chem	  Pharm	  Bull	  0	  2008	  2009	  2010	  Number	  of	  Submissions	140	126	

126	

120	
98	

100	
80	

74	

77	

Outside	

60	
40	

78	

47	

39	
Japan	

20	49	

0	2006	

2007	

2008	

2009	 2010	

79	2011!
(~October)	

•Number	  of	  submission	  is	  increasing.	  
•Submission	  from	  outside	  of	  Japan	  is	  increasing.	  	  	45	  40	  35	  30	  25	  20	  15	  10	  5	  enzyme	  transporter	  drug	  gene8cs	  metabolism	  PK	  physiology	  DDI	  nuclear	  receptor	  transcrip8on	  disease	  liver	  protein	  binding	  an8-­‐cancer	  drug	  inhibi8on	  modeling	  toxicity	  rat	  clinical	  study	  absorp8on	  human	  PG	  analysis	  DDS	  immune	  kidney	  excre8on	  intes8ne	  cell	  induc8on	  PK/PD	  receptor	  muta8on	  predic8on	  ethinic	  lung	  structure	  system	  biology	  drug	  discovery	  pharmacology	  natural	  product	  cancer	  screening	  permeability	  virus	  distribu8on	  physicochemistry	  mouse	  hormone	  brain	  PD	  cell	  organella	  phenotype	  blood	  dog	  RNAi	  monkey	  ARB	  heart	  therapy	  bacteria	  mechanism	  gene	  regula8on	  regenera8ve	  pig	  lipid	  vitamin	  amino	  acid	  channel	  diﬀeren8a8on	  transplanta8on	  biomarker	  individualiza8on	  skin	  spicies	  diﬀerence	  dye	  TDM	  others	  Frequency	  (%)	50	  Enzyme	Abbreviations:2010	  PK, pharmacokinetics;
Transporter	
2009	  DDI, Drug-drug interaction;
Drug	
2008	  PG, Pharmacogenomics;
Gene8cs	
ARB, angiotensin receptor blocker;
2007	  Metabolism	
Clinical	  Study	  PK	Absorp8on	  Physiology	
Human	  DDI	PG	  Nuclear	  Receptor	
Analysis	  Transcrip8on	
DDS	  
Disease	Immune	  Liver	Kidney	  Protein	  Binding	
Excre8on	  An8-­‐cancer	  Drug	
Intes8ne	  Inhibi8on	
Cell	  Modeling	
Toxicology	 Induc8on	  Rat	
PK/PD････	

0	  Keywords	

Perspectives in Drug Transporter Studies!
Drug transporter research will much more contribute to the pharmacotherapy
and drug-discovery/development. However, we need more effort for thepatients’ health care by establishment of “Personalized Medicine”.

Patients•Cloning	  •Structure-­‐func8on	  	  	  	  rela8onship	  •Transcrip8on	  &	  Sor8ng	  •In	  silico	  simula8on	  Basic•Tg/KO	  animal	  Academia
Industry•ES	  &	  iPS	  cells	  Regulation•Gene8c	  polymorphisms	  •Clinical	  informa8on	  •Expression	  proﬁles	  •Drug	  interac8on	  •Pathophysiology	  ClinicalDevelop •Biomarkers	  Hospital •Omics-­‐technologies	  Expected	  Topics	  &	  Programs	  in	  JSSX	  Annual	  Meetings	  by	  Members	  	  Others	  Transporters	  Event	  &	  its	  	  Solution	  Pharmacokinetics	  Regulatory	  Information	  Toxicity/PD/
Clinical	  PK/PD,	  TK/TD	  Human	  PK	  Prediction	  Drug	  	  Interaction	  Exploratory	  	  PK	  N=167	

The Requests to JSSX from Pharmaceutical Companies	Contribu)on	  to	  Drug	  Discoveries	  and	  Developments	  1. Informa8on	  for	  administra8on	  and	  regula8on	  2. Predic8on	  of	  clinical	  pharmacokine8cs,	  pharmacodynamics	  or	  toxicokine8cs	  3. Micro-­‐dosing	  study	  4. Transla8onal	  research	Drug	  Metab.	  Phannacokinet.	  26	  (5):	  441	  (2011).	  

Editorial	

The	  Challenge	  to	  Integrate	  Academic	  Research	  in	  Japan	  into	  Global	  R&D	  in	  Pharmaceu8cal	  Companies	

Takashi	  Igarashi,	  Ph.D.	  
JSSX	  Director	  (2010-­‐2011)	

Questionnaire Survey for Hospital Pharmacists	  Expected	  Themes	  &	  Programs	  Regarding	  Drug	  Metabolism	  and	  Pharmacokinetics	  	  Drug	  Development	  &	  DDS	  Pharmaceutical	  	  Care	  Drug	  Metabolism	  ・Proper	  Use	  of	  Antibiotics	  ・Proper	  Use	  of	  Anti-Cancer	  Drugs	  	  	  	  	  &	  Opioids	  ・Practice	  of	  TDM	  for	  Antiepileptic	  ・Basics	  &	  Practice	  of	  TDM	  Theory	  ・Estimation	  &	  Simulation	  Theory	  ・TDM	  for	  Anti-MRSA	  drugs	  ・Practice	  of	  Dosage	  Planning	  ・Dosage	  Control	  of	  Drugs	  	  	  	  	  Eliminated	  in	  Urine	  ・Proposal	  of	  Prescription	  Based	  	  	  	  	  on	  PK	  parameters	  ・Clinical	  Practice	  of	  PK/PD	  Theory	  ・Basic	  and	  Clinical	  Approaches	  of	  	  	  	  	  PKPD	  in	  Chemotherapy	  ・PKPD	  for	  Dosing	  Suggestions	  ・PKPD-Based	  Infection	  Therapy	  	  Proper	  Use	  of	  Drugs	  Ther	  Drug	  Monit	  	  Clinical	  Practice	  of	  PK-PD	  Approach	  Prescription	  &	  Dosing	  Control	  Drug	  Information	  ・Basics	  of	  PK/PD	  ・PK	  Approach	  for	  Prescription	  ・PK/PD	  of	  Anti-Cancer	  Drugs	  ・PK	  in	  Infants,	  Children	  &	  	  	  	  	  Pregnant	  Women	  Altered	  PK	  in	  	  Disease	  States	  N=294	・Dosing	  Planning	  for	  Patients	  with	  	  	  	  	  Hepatic/Renal	  Diseases	  ・Practice	  of	  Dosing	  Control	  in	  	  	  	  	  Disease	  States	  ・Dosage	  Control	  for	  Dialysis	  Patient	  The Requests to JSSX from Hospital Pharmacists	
For	  Op)mum	  Pharmacotherapy	  	  -­‐based	  on	  the	  knowledge	  of	  drug	  metabolism	  and	  pharmacokine)cs-­‐	1. 	  Knowledges	  about	  drug	  metabolism	  and	  disposi8on	  2. Technical	  skills	  for	  PK/PD	  approaches	  3. Pharmacokine8cs	  proﬁles	  of	  an8bio8cs,	  an8neoplas8c	  drugs,	  newly	  developed	  drugs	  4. Skill	  for	  TDM,	  dosage	  regimen	  and	  personalized	  medicine	Adaptation for Reform of The Pharmacy
Programs	
4	  years	  +	  2	  years	  +	  3	  years	
Educa8on	  for	  “Inves8gators	  of	  drug	  discovery	  and	  development”	
4	  years	

2	  years	

3	  years	

6	  years	  +	  4	  years	
Educa8on	  for	  the	  “Pharmacist-­‐Scien8sts”	
6	  years	

4	  years	・Admission	  of	  undergraduate	  students	  to	  JSSX	  EXPECTATIONS FOR "THE NEXT-GENERATION JSSX!
1. Noteworthy Research Outcomes Influential to World Wide!
2. Prominent Position as Academic Society in Drug Discovery and Development !
3. Application of Basic Research Outcomes to Clinical Pharmacotherapy!
4. Encouragement for Young Scientists and Pharmacist-Scientists !
5. More Globalization and Tight Partnership with ISSX	

Academia	

Clinical	  Pharmacists	

Pharmaceu8cal	  Companies	

Hiroshi	  Suzuki,	  Prof.,	  Ph.D.	  
The	  University	  of	  Tokyo	  Hospital	  	  Joint	  Scien8ﬁc	  Mee8ng	  of	  JSSX	  and	  ISSX	  	Mee)ng	  Co-­‐chairs	  	  Tetsuya	  Terasaki,	  PhD	   	  	  JSSX	  Tohoku	  University	  Eric	  Johnson,	  PhD	  	  	  	  ISSX	  The	  Scripps	  Research	  Ins8tute	
October	  12	  –	  17,	  2014	  in	  San	  Francisco,	  California,	  USA.